Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to buy Penumbra stock (PEN)

Buy Penumbra stock in 5 easy steps, view past price performance and learn what’s ahead for the company.

Penumbra is a medical devices business based in the US. Penumbra shares (PEN) are listed on the NYSE and all prices are listed in US Dollars. Penumbra employs 4,200 staff and has a trailing 12-month revenue of around $1.1 billion.

Our top picks for where to buy Penumbra stock

Top pick for advanced traders

Go to site
Get up to $5,000 cash
  • Trade options, futures, options on futures, stocks, ETFs
  • $0 commission to close options
  • Pro-grade platform and risk analysis tools

Best for beginners

Go to site
Get up to $10,000 cash
  • Trade stocks, options, ETFs, mutual funds, alternative asset funds
  • $0 commission on stocks, ETFs and options, with no options contract fees
  • No-cost financial planning and automated investing

Our pick for cash sweep

Go to site
Advanced charts and trading tools
  • Trade stocks, ETFs and equity options without commission and $0 option contract fees
  • Earn up to 8.1% APY on your uninvested cash
  • Get a 1.5% match in cash on transferred assets up to $300 or up to 15 free fractional shares worth between $2 and $2,000

How to buy Penumbra stock

  1. Choose a stock trading platform. Use our comparison table
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – PEN. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Buy Penumbra stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 4 of 4
Name Product Ratings Available asset types Stock trade fee Minimum deposit Cash sweep APY Signup bonus
Tastytrade
Finder Score: 4.4 / 5: ★★★★★
Tastytrade
★★★★★
Stocks, Options, ETFs, Cryptocurrency, Futures, Treasury Bills
$0
$0
N/A
Get $50-$5,000
Competitive, capped options commissions, with a reliable trading platform designed for serious traders.
SoFi Invest®
Finder Score: 4.2 / 5: ★★★★★
SoFi Invest®
★★★★★
Stocks, Options, Mutual funds, ETFs, Alternatives
$0
$0
0.02%
Get up to $10,000 cash
Commission-free stocks, ETFs and options, with no options per-contract fees. Plus, a no-cost robo-advisor and complimentary access to certified financial planners (CFPs).
Moomoo
Finder Score: 4.3 / 5: ★★★★★
Exclusive
Moomoo
★★★★★
Stocks, Options, ETFs
$0
$0
Up to 8.10%
Choose a 1.5% match or up to 15 free fractional shares
No commission stock, ETF and options trades, with $0 equity options contract fees, low margin rates and advanced trading tools.
Public.com
Finder Score: 4.2 / 5: ★★★★★
Public.com
★★★★★
Stocks, Bonds, Options, ETFs, Cryptocurrency, Alternatives, Treasury Bills, High-yield cash account
$0
$0
5.1%
Get up to $10,000 and transfer fees covered
Build a diversified portfolio of stocks, bonds, options, ETFs, crypto and alternative assets, with a high-yield cash account and options contract rebates.
loading

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Penumbra stock price (NYSE: PEN)

Use our graph to track the performance of PEN stocks over time.

Penumbra shares at a glance

Information last updated 2024-07-07.
Latest market close$186.29
52-week range$170.59 - $328.57
50-day moving average $193.18
200-day moving average $222.70
Wall St. target price$268.79
PE ratio 76.4093
Dividend yield N/A (0%)
Earnings per share (TTM) $2.37

Is it a good time to buy Penumbra stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Penumbra price performance over time

Historical closes compared with the close of $186.29 from 2024-07-11

1 week (2024-07-05) 2.87%
1 month (2024-06-12) -2.86%
3 months (2024-04-12) -14.33%
6 months (2024-01-12) -27.90%
1 year (2023-07-12) -41.41%
2 years (2022-07-12) 47.40%
3 years (2021-07-12) 271.6
5 years (2019-07-12) 9.78%

Is Penumbra stock undervalued or overvalued?

Valuing Penumbra stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Penumbra's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Penumbra's P/E ratio

Penumbra's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 76x. In other words, Penumbra shares trade at around 76x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Penumbra's EBITDA

Penumbra's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $121.8 million.

The EBITDA is a measure of a Penumbra's overall financial performance and is widely used to measure a its profitability.

Penumbra financials

Revenue TTM $1.1 billion
Operating margin TTM 4.34%
Gross profit TTM $535.2 million
Return on assets TTM 4.03%
Return on equity TTM 8.38%
Profit margin 8.52%
Book value $31.05
Market Capitalization $7 billion

TTM: trailing 12 months

Penumbra share dividends

We're not expecting Penumbra to pay a dividend over the next 12 months.

Have Penumbra's shares ever split?

Penumbra's shares were split on a 10:1 basis on 15 November 2014. So if you had owned 1 share the day before before the split, the next day you'd have owned 10 shares. This wouldn't directly have changed the overall worth of your Penumbra shares – just the quantity. However, indirectly, the new 90% lower share price could have impacted the market appetite for Penumbra shares which in turn could have impacted Penumbra's share price.

Penumbra share price volatility

Over the last 12 months, Penumbra's shares have ranged in value from as little as $170.59 up to $328.57. A popular way to gauge a stock's volatility is its "beta".

PEN.US volatility(beta: 0.56)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Penumbra's is 0.555. This would suggest that Penumbra's shares are less volatile than average (for this exchange).

Penumbra overview

Penumbra, Inc. , together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors.

Frequently asked questions

What percentage of Penumbra is owned by insiders or institutions?
Currently 3.819% of Penumbra shares are held by insiders and 88.173% by institutions.
How many people work for Penumbra?
Latest data suggests 4,200 work at Penumbra.
When does the fiscal year end for Penumbra?
Penumbra's fiscal year ends in December.
Where is Penumbra based?
Penumbra's address is: One Penumbra Place, Alameda, CA, United States, 94502
What is Penumbra's ISIN number?
Penumbra's international securities identification number is: US70975L1070
What is Penumbra's CUSIP number?
Penumbra's Committee on Uniform Securities Identification Procedures number is: 70975L107

More guides on Finder

Ask a Question

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site